Astellas looks to CV investors in bid to oust management
This article was originally published in Scrip
Executive Summary
Astellas is turning to CV Therapeutics' shareholders in a bid to oust the US firm's top management and replace it with a board more accepting of what has become its hostile $1.1 billion acquisition bid.